Real World Data (RWD) Market Report 2025

The real world data (RWD) market size has grown rapidly in recent years. It will grow from $1.73 billion in 2024 to $2.01 billion in 2025 at a compound annual growth rate (CAGR) of 16.3%. The growth during the historic period can be attributed to the increasing use of electronic health records, rising interest in value-based care, growing demand for post-marketing surveillance, an increasing prevalence of chronic diseases, and expanded availability of wearable health devices.

The real world data (RWD) market size is expected to see rapid growth in the next few years. It will grow to $3.64 billion in 2029 at a compound annual growth rate (CAGR) of 15.9%. The growth projected for the forecast period can be attributed to rising demand for personalized medicine, an increasing number of real-world evidence (RWE) submissions to regulatory bodies, growing focus on patient-centered outcomes, expanding penetration of telehealth services, and heightened emphasis on real-time patient monitoring. Key trends during this period include the development of interoperable systems, integration with genomic and biomarker data, innovations in real-time data processing, advancements in decentralized clinical trials, and improvements in data visualization tools.

The growing adoption of electronic health records (EHR) is expected to drive the expansion of the real-world data (RWD) market. Electronic health records are digital versions of patients’ medical charts that store and manage comprehensive health information to improve care coordination and clinical decision-making. This increased adoption is mainly driven by the need to enhance patient care and safety, as EHRs enable accurate, real-time access to patient data, reduce medical errors, and support better clinical decisions. Real-world data complements EHRs by offering insights into patient outcomes and treatment effectiveness in everyday clinical practice, facilitating more personalized and evidence-based care. For example, in June 2022, the UK’s Department of Health and Social Care reported that by March 2025, all NHS trusts had implemented electronic health records, up from 90% adoption by December 2023. Therefore, the rising adoption of EHRs is propelling growth in the real-world data market.

Key companies in the real-world data market are focusing on developing innovative solutions such as integrated analysis-ready datasets to streamline evidence generation and accelerate clinical decision-making. An integrated analysis-ready dataset is a cleaned, standardized, and combined data collection from multiple sources that can be used immediately for analysis without further preprocessing. For instance, in January 2025, US-based healthcare research firm Carelon Research, Inc. launched Carelon Real World Data, a comprehensive, analysis-ready dataset designed to improve healthcare evidence generation. This dataset integrates closed claims with electronic health records, providing detailed patient, provider, and payer information. It also includes enriched data on oncology, lab results, race and ethnicity, and social determinants of health. Built on decades of research, it is tailored to meet specific research needs and supports evidence generation across all therapeutic areas for life sciences teams.

In December 2023, Finland-based BC Platforms, a company specializing in building data networks for the life sciences sector, acquired Medexprim for an undisclosed amount. Through this acquisition, BC Platforms aims to expand its real-world data capabilities, particularly by integrating Medexprim’s clinical imaging expertise, thereby enhancing their ability to deliver comprehensive, multi-modal healthcare data solutions for research and innovation. Medexprim is a France-based software company that provides real-world data and real-world evidence solutions.

Major players in the real world data (rwd) market are Oracle Corporation, IQVIA Holdings Inc., ICON Public Limited Company, Syneos Health Inc., Parexel International Corporation, Revvity Inc., SAS Institute Inc., Datavant Inc., Palantir Technologies Inc., Tempus Labs Inc., Clarivate Plc, Flatiron Health Inc., Tempus Labs Inc., Clinigen Group plc, Komodo Health Inc., Aetion Inc., TriNetX LLC, Clarify Health Solutions Inc., Verana Health Inc., Evidation Health Inc., OM1 Inc., HealthVerity Inc., Pulse Infoframe Inc.

North America was the largest region in the real world data (RWD) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in real-world data (RWD) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the real-world data (RWD) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s recommendations and conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The rapid escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are significantly impacting the professional services sector, particularly in legal, consulting, architectural, and engineering domains. Higher costs for imported technology, software licenses, office equipment, and digital infrastructure have raised operational expenses for firms reliant on global tools and platforms. International consulting projects are facing delays or cost overruns due to increased travel expenses and restricted access to foreign-sourced data and tools. Additionally, clients in manufacturing, construction, and logistics, heavily affected by tariffs are cutting back on outsourced services, squeezing demand for professional expertise. As a result, service providers are reevaluating pricing structures, expanding domestic supplier relationships, and investing in AI-driven solutions to sustain profitability and client engagement amid economic uncertainty.

Real-world data (RWD) refers to health-related information collected outside traditional clinical trials from sources such as electronic health records (EHRs), insurance claims, patient registries, wearable devices, and patient-reported outcomes. It captures healthcare delivery and patient experiences in real-life settings. The primary goal of RWD is to provide insights into treatment performance across broader, more diverse populations under real-world conditions. It supports regulatory decisions, drug development, post-market surveillance, and personalized medicine by complementing data from controlled clinical trials.

The main components of real-world data (RWD) include services and datasets. Services encompass professional solutions that assist in data collection, analysis, integration, and interpretation within healthcare and research, helping transform raw data into actionable insights for decision-making and development. RWD is applied in various areas such as drug development and approvals, market access, reimbursement and coverage decisions, post-market surveillance, clinical research, and more. It serves a broad range of end users, including pharmaceutical and medical device companies, healthcare payers, healthcare providers, government agencies, and others.

The real-world data (RWD) market research report is one of a series of new reports that provides real-world data (RWD) market statistics, including real-world data (RWD) global market size, regional shares, competitors with real-world data (RWD) market share, detailed real-world data (RWD) market segments, market trends and opportunities, and any further data you may need to thrive in the real-world data (RWD) industry. The real-world data (RWD) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The real-world data (RWD) market includes revenues earned by entities by providing services, such as data collection services, data aggregation and integration, data analytics and insights, data licensing and subscription, and real-time monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.